JP2012072152A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012072152A5 JP2012072152A5 JP2011236920A JP2011236920A JP2012072152A5 JP 2012072152 A5 JP2012072152 A5 JP 2012072152A5 JP 2011236920 A JP2011236920 A JP 2011236920A JP 2011236920 A JP2011236920 A JP 2011236920A JP 2012072152 A5 JP2012072152 A5 JP 2012072152A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- pdgf
- antibody
- vegf
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 11
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 11
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 4
- 201000000159 corneal neovascularization Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims 28
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 8
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 6
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 description 26
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 9
- 238000002648 combination therapy Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 229940005014 pegaptanib sodium Drugs 0.000 description 6
- 210000004087 cornea Anatomy 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- UIYWFOZZIZEEKJ-XVFCMESISA-N 1-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical group F[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 UIYWFOZZIZEEKJ-XVFCMESISA-N 0.000 description 3
- ZTCKUVQHKIMCLI-UHFFFAOYSA-N 3-[2-[2-[2-[2-[2-[2-[bis(4-methoxyphenyl)-phenylmethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy-[di(propan-2-yl)amino]phosphanyl]oxypropanenitrile Chemical compound C1=CC(OC)=CC=C1C(OCCOCCOCCOCCOCCOCCOP(OCCC#N)N(C(C)C)C(C)C)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 ZTCKUVQHKIMCLI-UHFFFAOYSA-N 0.000 description 3
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229960004184 ketamine hydrochloride Drugs 0.000 description 3
- 229940092110 macugen Drugs 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 2
- HLBRKRLKOQTVRY-UHFFFAOYSA-N 2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxyphosphonamidous acid Chemical compound NP(O)OCCOCCOCCOCCOCCO HLBRKRLKOQTVRY-UHFFFAOYSA-N 0.000 description 2
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101150044441 PECAM1 gene Proteins 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001775 bruch membrane Anatomy 0.000 description 2
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- TYJOQICPGZGYDT-UHFFFAOYSA-N 4-methylsulfonylbenzenesulfonyl chloride Chemical compound CS(=O)(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 TYJOQICPGZGYDT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000004233 retinal vasculature Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 229960004175 xylazine hydrochloride Drugs 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49840703P | 2003-08-27 | 2003-08-27 | |
| US60/498,407 | 2003-08-27 | ||
| US55683704P | 2004-03-26 | 2004-03-26 | |
| US60/556,837 | 2004-03-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006524824A Division JP4951339B2 (ja) | 2003-08-27 | 2004-08-26 | 眼血管新生疾患の治療のための併用療法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014147781A Division JP2014237674A (ja) | 2003-08-27 | 2014-07-18 | 眼血管新生疾患の治療のための併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012072152A JP2012072152A (ja) | 2012-04-12 |
| JP2012072152A5 true JP2012072152A5 (cg-RX-API-DMAC7.html) | 2013-02-21 |
Family
ID=34278595
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006524824A Expired - Fee Related JP4951339B2 (ja) | 2003-08-27 | 2004-08-26 | 眼血管新生疾患の治療のための併用療法 |
| JP2011236920A Pending JP2012072152A (ja) | 2003-08-27 | 2011-10-28 | 眼血管新生疾患の治療のための併用療法 |
| JP2014147781A Withdrawn JP2014237674A (ja) | 2003-08-27 | 2014-07-18 | 眼血管新生疾患の治療のための併用療法 |
| JP2016134790A Pending JP2017014215A (ja) | 2003-08-27 | 2016-07-07 | 眼血管新生疾患の治療のための併用療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006524824A Expired - Fee Related JP4951339B2 (ja) | 2003-08-27 | 2004-08-26 | 眼血管新生疾患の治療のための併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014147781A Withdrawn JP2014237674A (ja) | 2003-08-27 | 2014-07-18 | 眼血管新生疾患の治療のための併用療法 |
| JP2016134790A Pending JP2017014215A (ja) | 2003-08-27 | 2016-07-07 | 眼血管新生疾患の治療のための併用療法 |
Country Status (18)
| Country | Link |
|---|---|
| US (9) | US7759472B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2281885A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP4951339B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR101501870B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN102380098B (cg-RX-API-DMAC7.html) |
| AR (1) | AR046682A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2004268614C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0413977A (cg-RX-API-DMAC7.html) |
| CA (3) | CA2536912C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1113058T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1660057T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2388138T3 (cg-RX-API-DMAC7.html) |
| NZ (4) | NZ617083A (cg-RX-API-DMAC7.html) |
| PL (1) | PL1660057T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1660057E (cg-RX-API-DMAC7.html) |
| SI (1) | SI1660057T1 (cg-RX-API-DMAC7.html) |
| TW (3) | TWI484964B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005020972A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US20120183593A1 (en) * | 2003-04-09 | 2012-07-19 | Directcontact Llc | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| WO2004094614A2 (en) * | 2003-04-21 | 2004-11-04 | Archemix Corp. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| NZ617083A (en) * | 2003-08-27 | 2015-04-24 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| ES2439390T3 (es) * | 2004-06-04 | 2014-01-22 | The Scripps Research Institute | Composiciones y procedimiento para el tratamiento de enfermedades neovasculares |
| EP2324848A3 (en) * | 2004-10-21 | 2011-09-14 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
| US20060257359A1 (en) * | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| PL2586459T3 (pl) | 2005-03-25 | 2017-12-29 | Regeneron Pharmaceuticals, Inc. | Formulacje antagonistów vegf |
| IL172297A (en) | 2005-10-03 | 2016-03-31 | Compugen Ltd | Soluble vegfr-1 variants for the diagnosis of preeclampsia |
| CN101330929B (zh) * | 2005-10-14 | 2014-03-05 | 学校法人福冈大学 | 胰岛移植中的移植胰岛障碍抑制剂 |
| JP5191235B2 (ja) * | 2005-10-21 | 2013-05-08 | 中外製薬株式会社 | 心疾患治療剤 |
| AR057582A1 (es) * | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| US20090269335A1 (en) * | 2005-11-25 | 2009-10-29 | Keio University | Therapeutic agent for prostate cancer |
| EP1968643A2 (en) * | 2005-12-16 | 2008-09-17 | Diatos | Cell penetrating peptide conjugates for delivering of nucleic acids into a cell |
| AR057252A1 (es) * | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares |
| US8673873B1 (en) * | 2005-12-28 | 2014-03-18 | Alcon Research, Ltd. | RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders |
| CN104189907A (zh) * | 2006-01-27 | 2014-12-10 | 学校法人庆应义塾 | 伴有脉络膜血管生成的疾病的治疗药 |
| CA2622312A1 (en) * | 2006-01-30 | 2007-08-02 | (Osi) Eyetech, Inc. | Combination therapy for the treatment of neovascular disorders |
| AU2013204622B2 (en) * | 2006-03-08 | 2016-04-21 | Archemix Llc | Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders |
| CN104623692A (zh) * | 2006-03-08 | 2015-05-20 | 阿切埃米克斯股份有限公司 | 治疗视觉失调中使用的补体结合适体和抗-c5药物 |
| US9260516B2 (en) * | 2006-04-07 | 2016-02-16 | Osaka University | Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor |
| US20070258976A1 (en) * | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
| CN101478949A (zh) | 2006-06-16 | 2009-07-08 | 瑞泽恩制药公司 | 适合玻璃体内施用的vegf拮抗剂的制剂 |
| US20080081791A1 (en) * | 2006-07-06 | 2008-04-03 | Weida Huang | Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi |
| US7947447B2 (en) | 2007-01-16 | 2011-05-24 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| KR101508019B1 (ko) * | 2007-01-23 | 2015-04-06 | 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 | 만성 거부반응 억제제 |
| WO2008103320A1 (en) * | 2007-02-16 | 2008-08-28 | Novacea, Inc. | Methods of treating ophthalmic disorders with anthraquinones |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| US20080286338A1 (en) * | 2007-05-15 | 2008-11-20 | Boston Foundation For Sight | Drug delivery system with scleral lens |
| WO2009120922A2 (en) | 2008-03-27 | 2009-10-01 | Zymogenetics, Inc. | Compositions and methods for inhibiting pdgfrbeta and vegf-a |
| CA2728243C (en) * | 2008-06-05 | 2020-03-10 | National Cancer Center | Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer |
| WO2010097800A1 (en) * | 2009-02-26 | 2010-09-02 | Muhammad Abdulrazik | Synergistic combination of bioactive compounds for lowering of intraocular pressure |
| EP3028707A1 (en) * | 2009-05-01 | 2016-06-08 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
| WO2015073571A1 (en) | 2013-11-15 | 2015-05-21 | Dose Medical Corporation | Ocular implants configured to store and release stable drug formulations |
| WO2012071476A2 (en) | 2010-11-24 | 2012-05-31 | David Haffner | Drug eluting ocular implant |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
| SI2578231T1 (sl) | 2010-05-28 | 2023-01-31 | Chugai Seiyaku Kabushiki Kaisha | Okrepljen protitumorski T celični odzivnik |
| US20120041047A1 (en) * | 2010-08-10 | 2012-02-16 | Gene Signal International Sa | Injectable Pharmaceutical Composition for Preventing, Stabilizing and/or Inhibiting Pathological Neovascularization-Related Conditions |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| US9682144B2 (en) | 2011-06-30 | 2017-06-20 | Gene Signal International, Sa | Composition comprising inhibitors of IRS-1 and of VEGF |
| GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| EP2755549A1 (en) | 2011-09-13 | 2014-07-23 | Dose Medical Corporation | Intraocular physiological sensor |
| CA3098762C (en) | 2012-03-26 | 2023-01-17 | Glaukos Corporation | System and method for delivering multiple ocular implants |
| ES2742284T3 (es) | 2012-03-28 | 2020-02-13 | Somalogic Inc | Aptámeros contra PDGF y VEGF y su utilización en el tratamiento de afecciones mediadas por PDGF y VEGF |
| WO2013181495A2 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corporation | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| KR101386697B1 (ko) * | 2012-06-18 | 2014-04-18 | 아주대학교산학협력단 | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
| AU2013283296A1 (en) | 2012-06-28 | 2015-02-05 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| AU2013100071C4 (en) * | 2012-07-03 | 2013-05-02 | Novartis Ag | Device |
| GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
| WO2014052518A1 (en) | 2012-09-27 | 2014-04-03 | Allergan, Inc. | Biodegradable drug delivery systems for the sustained release of proteins |
| NZ706853A (en) | 2012-10-11 | 2018-04-27 | Ascendis Pharma Ophthalmology Div A/S | Vegf neutralizing prodrugs for the treatment of ocular conditions |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| PH12015501492A1 (en) | 2013-01-08 | 2015-09-28 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
| US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
| CN105452240B (zh) | 2013-05-23 | 2018-06-26 | 卡尔维斯塔制药有限公司 | 杂环衍生物 |
| CN103254286A (zh) * | 2013-05-30 | 2013-08-21 | 苏州普罗达生物科技有限公司 | 一种vegfr2酪氨酸激酶抑制剂多肽及其应用 |
| RU2676303C2 (ru) * | 2013-07-11 | 2018-12-27 | Новартис Аг | Использование антагониста vegf для лечения ретролентальной фиброплазии |
| KR20230152151A (ko) | 2013-07-12 | 2023-11-02 | 이베릭 바이오, 인크. | 안과적 질환을 치료하거나 예방하기 위한 방법 |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| PL3033336T3 (pl) | 2013-08-14 | 2018-11-30 | Kalvista Pharmaceuticals Limited | Inhibitory kalikreiny w plaźmie |
| GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
| LT3041513T (lt) | 2013-09-08 | 2020-11-25 | Kodiak Sciences Inc. | Viii faktoriaus cviterioninių polimerų konjugatai |
| ES2834910T3 (es) | 2013-09-09 | 2021-06-21 | Somalogic Inc | Aptámeros de PDGF y VEGF que tienen una estabilidad mejorada y su uso en el tratamiento de enfermedades y trastornos mediados por PDGF y VEGF |
| CA2950187A1 (en) | 2014-05-29 | 2015-12-03 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| DK3170005T3 (da) | 2014-07-18 | 2019-07-08 | Sanofi Sa | Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer |
| WO2016022914A1 (en) * | 2014-08-08 | 2016-02-11 | Moderna Therapeutics, Inc. | Compositions and methods for the treatment of ophthalmic diseases and conditions |
| JP6849590B2 (ja) | 2014-10-17 | 2021-03-24 | コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． | ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート |
| MX2017005975A (es) * | 2014-11-10 | 2017-06-29 | Hoffmann La Roche | Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso. |
| GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| KR101721059B1 (ko) * | 2014-12-26 | 2017-03-30 | 주식회사 아이바이오코리아 | 안구 표면 질환 예방 또는 치료용 약학조성물 |
| WO2016191277A1 (en) * | 2015-05-22 | 2016-12-01 | Indiana University Research & Technology Corporation | Methods and systems for patient specific identification and assessment of ocular disease risk factors and treatment efficacy |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| EP3954709A1 (en) | 2015-10-02 | 2022-02-16 | F. Hoffmann-La Roche AG | Bispecific antibodies specific for pd1 and tim3 |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| ES2819030T3 (es) | 2016-04-08 | 2021-04-14 | Eyebio Korea | Péptido basado en colágeno tipo II alfa-1 útil para el tratamiento de una enfermedad de la superficie ocular |
| CN115120405A (zh) | 2016-04-20 | 2022-09-30 | 多斯医学公司 | 生物可吸收眼部药物的递送装置 |
| ME03794B (me) | 2016-05-31 | 2021-04-20 | Kalvista Pharmaceuticals Ltd | Derivati pirazola kao inhibitori kalikreina plazme |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| RU2669787C2 (ru) * | 2016-12-13 | 2018-10-16 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Средство для лечения заболевания, сопровождающегося отеком макулы вследствие повышенной экспрессии VEGF-A |
| UA125700C2 (uk) | 2017-04-03 | 2022-05-18 | Ф. Хоффманн-Ля Рош Аг | Імунокон'югати антитіла до pd-1 з мутантом il-2 |
| MA49038B1 (fr) | 2017-04-05 | 2025-01-31 | F. Hoffmann-La Roche Ag | Anticorps bispécifiques se liant particulièrement à pd1 et lag3 |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| US11857262B2 (en) | 2017-09-29 | 2024-01-02 | Glaukos Corporation | Intraocular physiological sensor |
| WO2019075270A1 (en) | 2017-10-12 | 2019-04-18 | Amesino Llc | VEGFR ANTIBODY LIGHT CHAIN FUSION PROTEIN |
| EP3698808B1 (en) | 2017-10-20 | 2025-01-01 | Hyogo College Of Medicine | Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| DK3716952T3 (da) | 2017-11-29 | 2022-03-14 | Kalvista Pharmaceuticals Ltd | Doseringsformer omfattende en plasmakallikrein-inhibitor |
| WO2019169341A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| WO2019210097A1 (en) * | 2018-04-25 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Aptamers with stability, potency or half-life for enhanced safety and efficacy |
| CN116585466A (zh) | 2018-05-10 | 2023-08-15 | 瑞泽恩制药公司 | 含有高浓度vegf受体融合蛋白的制剂 |
| CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
| WO2021032936A1 (en) | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| PH12022550124A1 (en) | 2019-08-21 | 2022-11-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| CN114258392A (zh) | 2019-08-21 | 2022-03-29 | 卡尔维斯塔制药有限公司 | 酶抑制剂 |
| BR112022001341A2 (pt) | 2019-08-21 | 2022-03-22 | Kalvista Pharmaceuticals Ltd | Inibidores de enzima |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| WO2021198034A1 (en) | 2020-03-30 | 2021-10-07 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf and pdgf-b and methods of use |
| MX2022015327A (es) * | 2020-06-05 | 2023-02-22 | Occurx Pty Ltd | Compuestos y metodos para el tratamiento de trastornos oculares. |
| JP2023552747A (ja) | 2020-12-01 | 2023-12-19 | カルビスタ・ファーマシューティカルズ・リミテッド | 酵素阻害剤 |
| CN114366712B (zh) * | 2022-01-25 | 2023-10-24 | 上海交通大学医学院附属第九人民医院 | 用于治疗脉络膜新生血管的药物凝胶混合物 |
| CN117100874B (zh) * | 2022-05-16 | 2025-10-31 | 苏州维益生物科技有限公司 | 纳米颗粒、其制备和应用、及包括其的眼疾药物及其制备 |
| TW202412765A (zh) | 2022-08-18 | 2024-04-01 | 英商卡爾維斯塔製藥有限公司 | 酶抑制劑 |
| WO2024218503A1 (en) | 2023-04-20 | 2024-10-24 | Kalvista Pharmaceuticals Limited | Solid forms of an enzyme inhibitor and salts thereof |
Family Cites Families (188)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US976534A (en) | 1909-09-15 | 1910-11-22 | August Wolff | Window. |
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
| FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| FR2594438B1 (fr) | 1986-02-14 | 1990-01-26 | Labaz Sanofi Nv | Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant |
| US5322691A (en) * | 1986-10-02 | 1994-06-21 | Sohrab Darougar | Ocular insert with anchoring protrusions |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| CA1340032C (en) | 1987-06-24 | 1998-09-08 | Jim Haralambidis | Lucleoside derivatives |
| IL87181A (en) | 1987-08-07 | 1993-08-18 | Sanofi Sa | Aminoalkoxyphenyl derivatives, their preparation and pharmaceutical and veterinary compositions containing them |
| US4914210A (en) | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
| US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
| US5468468A (en) | 1989-02-09 | 1995-11-21 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Method for making a monoclonal antibody, monoclonal antibodies to α PD |
| US5244805A (en) | 1989-05-17 | 1993-09-14 | University Of Georgia Research Foundation, Inc. | Baculovirus expression vectors |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
| US5225347A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
| US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
| US6005087A (en) | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
| US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
| US5707796A (en) | 1990-06-11 | 1998-01-13 | Nexstar Pharmaceuticals, Inc. | Method for selecting nucleic acids on the basis of structure |
| DE69128350T2 (de) | 1990-06-11 | 1998-03-26 | Nexstar Pharmaceuticals Inc | Nukleinsäureliganden |
| US5668264A (en) | 1990-06-11 | 1997-09-16 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5674685A (en) | 1990-06-11 | 1997-10-07 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
| US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US6465188B1 (en) | 1990-06-11 | 2002-10-15 | Gilead Sciences, Inc. | Nucleic acid ligand complexes |
| US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| US5811533A (en) | 1990-06-11 | 1998-09-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US6147204A (en) | 1990-06-11 | 2000-11-14 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US6168778B1 (en) | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
| US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5459015A (en) | 1990-06-11 | 1995-10-17 | Nexstar Pharmaceuticals, Inc. | High-affinity RNA ligands of basic fibroblast growth factor |
| US5683867A (en) | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
| US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
| ATE154246T1 (de) | 1990-07-27 | 1997-06-15 | Isis Pharmaceuticals Inc | Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| AU648630B2 (en) | 1990-12-21 | 1994-04-28 | Creative Biomolecules, Inc. | Biosynthetic PDGF antagonists |
| AU1411092A (en) | 1991-01-31 | 1992-09-07 | Cor Therapeutics, Inc. | Domains of extracellular region of human platelet derived growth factor receptor polypeptides |
| GB9106678D0 (en) | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| EP0584222B1 (en) | 1991-05-10 | 1997-10-08 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| US6762290B1 (en) | 1999-07-29 | 2004-07-13 | Gilead Sciences, Inc. | High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
| US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
| TW393513B (en) | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
| EP0637965B1 (en) | 1991-11-26 | 2002-10-16 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
| US5817310A (en) | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
| US5238950A (en) | 1991-12-17 | 1993-08-24 | Schering Corporation | Inhibitors of platelet-derived growth factor |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| TW225528B (cg-RX-API-DMAC7.html) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5756291A (en) | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
| US5869462A (en) | 1992-09-10 | 1999-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
| US5821234A (en) | 1992-09-10 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of proliferation of vascular smooth muscle cell |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5620687A (en) | 1993-02-25 | 1997-04-15 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors |
| US5976534A (en) | 1993-02-25 | 1999-11-02 | Zymogenetics, Inc. | Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin |
| US5731294A (en) | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
| US6410322B1 (en) | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
| US5641756A (en) * | 1993-07-27 | 1997-06-24 | Hybridon, Inc. | Modified VEGF oligonucleotides |
| US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
| US5952304A (en) | 1993-10-22 | 1999-09-14 | Trigen Limited | Platelet-derived growth factor analogues |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
| WO1995016032A1 (en) * | 1993-12-09 | 1995-06-15 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF DISEASES IN WHICH EXPRESSION OF bFGF, PDGF-A OR PDGF-B PLAYS A PATHOGENIC ROLE |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| US6448077B1 (en) | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
| US5840301A (en) | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
| US5861499A (en) | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
| US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US5958942A (en) | 1994-07-15 | 1999-09-28 | Takeda Chemical Industries, Ltd. | Tricyclic nitrogen ring compounds, their production and use |
| CA2156767A1 (en) | 1994-08-25 | 1996-02-26 | Kenichi Matsunaga | Binding agent for growth factor |
| US5476851A (en) | 1994-09-08 | 1995-12-19 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase |
| US5795910A (en) | 1994-10-28 | 1998-08-18 | Cor Therapeutics, Inc. | Method and compositions for inhibiting protein kinases |
| US6403088B1 (en) | 1995-08-01 | 2002-06-11 | Helsinki University Licensing, Ltd. | Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3) |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5723750A (en) | 1995-01-12 | 1998-03-03 | Vanderbilt University | Transgenic plants expressing disassembly deficient viral coat proteins |
| US5928939A (en) | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
| US5611135A (en) | 1995-03-21 | 1997-03-18 | Dana Corporation | Method of making a tube yoke for drive line assembly |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5859228A (en) | 1995-05-04 | 1999-01-12 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| EP1741780A3 (en) * | 1995-06-02 | 2007-03-28 | Gilead Sciences, Inc. | High affinity oligonucleotide ligands to growth factors |
| US5723594A (en) | 1995-06-07 | 1998-03-03 | Nexstar Pharmaceuticals, Inc. | High affinity PDGF nucleic acid ligands |
| US5618837A (en) | 1995-06-07 | 1997-04-08 | Zymogenetics, Inc. | PDGF antagonists III |
| US6229002B1 (en) * | 1995-06-07 | 2001-05-08 | Nexstar Pharmaceuticlas, Inc. | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
| US6699843B2 (en) * | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
| DE69632402T2 (de) | 1995-06-30 | 2005-05-19 | Zymogenetics, Inc., Seattle | 4-(2-(n-(-2-carboxamidoindole)aminiethyl)-benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste |
| US6361946B1 (en) | 1997-02-05 | 2002-03-26 | Licentia Ltd | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
| US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| PT848755E (pt) | 1995-09-08 | 2003-12-31 | Genentech Inc | Proteina relacionada com o vegf |
| AU1686997A (en) | 1995-12-08 | 1997-06-27 | Hybridon, Inc. | Modified vegf antisense oligonucleotides for treatment of skin disorders |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| IL125954A (en) | 1996-03-05 | 2003-06-24 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect |
| JP2000506880A (ja) | 1996-03-15 | 2000-06-06 | ゼネカ・リミテッド | シンノリン誘導体及びその使用 |
| US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
| WO1997040830A1 (en) | 1996-05-01 | 1997-11-06 | Eli Lilly And Company | Therapeutic treatment for vegf related diseases |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| FR2752734B1 (fr) | 1996-09-02 | 1998-11-06 | Cird Galderma | Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf |
| EP0928203B1 (en) | 1996-09-24 | 2006-10-25 | Merck & Co., Inc. | Compounds for the inhibition of angiogenesis by gene therapy |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| CA2239227C (en) | 1996-10-01 | 2007-10-30 | Kenji Matsuno | Nitrogen-containing heterocyclic compounds |
| US6051698A (en) * | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| US6426335B1 (en) | 1997-10-17 | 2002-07-30 | Gilead Sciences, Inc. | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| WO1998031794A1 (fr) | 1997-01-17 | 1998-07-23 | Toa Gosei Co., Ltd. | Polypeptide liant le facteur vegf |
| US6291667B1 (en) | 1997-01-31 | 2001-09-18 | Parkash S. Gill | Method and composition for treatment of kaposi's sarcoma |
| US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ATE293640T1 (de) * | 1997-04-07 | 2005-05-15 | Genentech Inc | Anti-vegf antikörper |
| US7365166B2 (en) * | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US6180632B1 (en) | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| US6278039B1 (en) | 1997-05-28 | 2001-08-21 | Axys Pharmaceuticals, Inc. | C. elegans deletion mutants |
| US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| US6159978A (en) | 1997-05-28 | 2000-12-12 | Aventis Pharmaceuticals Product, Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| US5932580A (en) | 1997-12-01 | 1999-08-03 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | PDGF receptor kinase inhibitory compounds their preparation and compositions |
| US6251588B1 (en) | 1998-02-10 | 2001-06-26 | Agilent Technologies, Inc. | Method for evaluating oligonucleotide probe sequences |
| AU780593B2 (en) | 1998-10-19 | 2005-04-07 | Licentia Ltd | Novel neuropilin/growth factor binding and uses thereof |
| DE69931178T8 (de) | 1998-11-02 | 2007-06-28 | Ludwig Institute For Cancer Research | Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2 |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| EP1135498B1 (en) | 1998-11-18 | 2008-01-23 | Genentech, Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| ES2259247T3 (es) | 1998-12-21 | 2006-09-16 | Ludwig Institute For Cancer Research | Anticuerpos frente a vegf-d truncado y sus usos. |
| US6110462A (en) | 1999-03-03 | 2000-08-29 | The Scripps Research Institute | Enzymatic DNA molecules that contain modified nucleotides |
| AU4028800A (en) | 1999-04-02 | 2000-10-23 | City Of Hope | Method for identifying accessible binding sites on rna |
| CN1308347C (zh) | 1999-04-28 | 2007-04-04 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
| US7070959B1 (en) * | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7306799B2 (en) * | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US7303746B2 (en) * | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US6382219B1 (en) * | 1999-06-08 | 2002-05-07 | Jeffery A. Jelten | Tooth flossing device |
| US7078390B1 (en) * | 1999-10-15 | 2006-07-18 | Gentier Biosystems Incorporation | Ribozymes to growth factor originating in human platelet |
| PT1473003E (pt) * | 1999-10-21 | 2008-12-26 | Alcon Inc | Dispositivo para administração de fármacos |
| US6358954B1 (en) | 1999-11-09 | 2002-03-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| CA2404528A1 (en) | 2000-03-31 | 2001-10-04 | Institut Pasteur | Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| AU2001263251A1 (en) * | 2000-05-17 | 2001-11-26 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to pdgf |
| EP1992317B1 (en) | 2000-08-30 | 2012-02-29 | Johns Hopkins University | Devices for intraocular drug delivery |
| WO2003070910A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2004003211A1 (en) | 2002-06-26 | 2004-01-08 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| FR2828601B1 (fr) | 2001-08-10 | 2003-11-07 | Iroc Technologies | Ensemble de circuits electroniques comportant des moyens de decontamination de parties contaminees par des erreurs |
| US6927293B2 (en) * | 2001-08-30 | 2005-08-09 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1436329A4 (en) | 2001-09-20 | 2005-04-27 | Alexion Pharma Inc | ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING FOCUSED ANTIBODIES |
| EA006746B1 (ru) | 2001-11-09 | 2006-04-28 | Айтек Фармасьютикалз | Способы лечения глазных неоваскулярных заболеваний |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| AR037647A1 (es) | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| EP1552002A4 (en) | 2002-06-18 | 2006-02-08 | Archemix Corp | APTAMER TOXIN MOLECULES AND METHOD FOR THEIR USE |
| US20040249130A1 (en) | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| US20070184089A1 (en) * | 2002-07-15 | 2007-08-09 | Alcon, Inc. | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use |
| TWI283406B (en) * | 2002-08-28 | 2007-07-01 | Brilliance Semiconductor Inc | Charging-free ultra-low power virtual dynamic random access memory |
| US8003117B2 (en) | 2002-11-20 | 2011-08-23 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
| JP4412461B2 (ja) | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
| US8828373B2 (en) | 2002-11-20 | 2014-09-09 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
| US10100316B2 (en) | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
| US20040253243A1 (en) | 2003-01-21 | 2004-12-16 | David Epstein | Aptamer therapeutics useful in ocular pharmacotherapy |
| CA2504633A1 (en) | 2002-11-21 | 2004-06-10 | Archemix Corporation | Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same |
| US20050124565A1 (en) | 2002-11-21 | 2005-06-09 | Diener John L. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US8039443B2 (en) | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
| US20090053138A1 (en) | 2002-11-21 | 2009-02-26 | Preiss Jeffrey R | Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology Therapeutics |
| US7459436B2 (en) * | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
| US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| EP1639001A1 (en) * | 2003-06-27 | 2006-03-29 | Dnavec Research Inc. | Method for transplanting lymphohematopoietic cells into mammal |
| NZ617083A (en) | 2003-08-27 | 2015-04-24 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| US20050063257A1 (en) * | 2003-09-24 | 2005-03-24 | Clark David G. | Audio bookmark |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| US20050244471A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
| US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
| US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US20050244462A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
| AU2006214658A1 (en) * | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| US7354581B2 (en) | 2005-02-11 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a VEGF antagonist and anti-hypertensive agent |
| US20090075342A1 (en) | 2005-04-26 | 2009-03-19 | Sharon Cload | Metabolic profile directed aptamer medicinal chemistry |
| DK2029746T3 (da) | 2006-06-12 | 2012-10-08 | Exegenics Inc D B A Opko Health Inc | Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogenese |
| CN101478949A (zh) * | 2006-06-16 | 2009-07-08 | 瑞泽恩制药公司 | 适合玻璃体内施用的vegf拮抗剂的制剂 |
| MX2009006146A (es) * | 2006-12-18 | 2009-06-19 | Alcon Res Ltd | Dispositivos y metodos para la administracion de farmacos oftalmicos. |
| CA2690858A1 (en) | 2007-06-07 | 2008-12-18 | Surmodics Pharmaceuticals, Inc. | Reduced-mass, long-acting dosage forms |
| EP3028707A1 (en) | 2009-05-01 | 2016-06-08 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
| CN102122763A (zh) * | 2011-03-17 | 2011-07-13 | 东南大学 | 并联馈电的全向阵列天线 |
-
2004
- 2004-08-26 NZ NZ61708304A patent/NZ617083A/en not_active IP Right Cessation
- 2004-08-26 JP JP2006524824A patent/JP4951339B2/ja not_active Expired - Fee Related
- 2004-08-26 EP EP20100013061 patent/EP2281885A1/en not_active Withdrawn
- 2004-08-26 CN CN201110271111.2A patent/CN102380098B/zh not_active Expired - Fee Related
- 2004-08-26 KR KR1020137034182A patent/KR101501870B1/ko not_active Expired - Fee Related
- 2004-08-26 CA CA2536912A patent/CA2536912C/en not_active Expired - Fee Related
- 2004-08-26 ES ES04782166T patent/ES2388138T3/es not_active Expired - Lifetime
- 2004-08-26 PL PL04782166T patent/PL1660057T3/pl unknown
- 2004-08-26 DK DK04782166.5T patent/DK1660057T3/da active
- 2004-08-26 NZ NZ592039A patent/NZ592039A/xx not_active IP Right Cessation
- 2004-08-26 PT PT04782166T patent/PT1660057E/pt unknown
- 2004-08-26 AU AU2004268614A patent/AU2004268614C1/en not_active Ceased
- 2004-08-26 NZ NZ546088A patent/NZ546088A/en not_active IP Right Cessation
- 2004-08-26 CN CN2004800317001A patent/CN1934255B/zh not_active Expired - Fee Related
- 2004-08-26 WO PCT/US2004/027612 patent/WO2005020972A2/en not_active Ceased
- 2004-08-26 KR KR1020127022927A patent/KR101471732B1/ko not_active Expired - Fee Related
- 2004-08-26 EP EP16002068.1A patent/EP3168304A1/en not_active Withdrawn
- 2004-08-26 SI SI200431912T patent/SI1660057T1/sl unknown
- 2004-08-26 CA CA2903196A patent/CA2903196A1/en not_active Abandoned
- 2004-08-26 EP EP04782166A patent/EP1660057B1/en not_active Expired - Lifetime
- 2004-08-26 US US10/926,806 patent/US7759472B2/en not_active Expired - Fee Related
- 2004-08-26 NZ NZ601544A patent/NZ601544A/xx not_active IP Right Cessation
- 2004-08-26 CA CA2876822A patent/CA2876822C/en not_active Expired - Fee Related
- 2004-08-26 BR BRPI0413977-1A patent/BRPI0413977A/pt not_active IP Right Cessation
- 2004-08-26 KR KR1020067004047A patent/KR101218889B1/ko not_active Expired - Fee Related
- 2004-08-26 CN CN201210165474.2A patent/CN102813923B/zh not_active Expired - Fee Related
- 2004-08-27 TW TW102122763A patent/TWI484964B/zh not_active IP Right Cessation
- 2004-08-27 TW TW103128503A patent/TWI484965B/zh not_active IP Right Cessation
- 2004-08-27 TW TW093125925A patent/TWI414300B/zh not_active IP Right Cessation
- 2004-08-27 AR ARP040103086A patent/AR046682A1/es unknown
-
2009
- 2009-05-13 US US12/465,051 patent/US8206707B2/en not_active Expired - Fee Related
- 2009-09-22 US US12/564,863 patent/US8187597B2/en not_active Expired - Fee Related
- 2009-12-17 US US12/641,270 patent/US8685397B2/en not_active Expired - Fee Related
-
2010
- 2010-09-24 AU AU2010224423A patent/AU2010224423B2/en not_active Ceased
-
2011
- 2011-01-10 US US12/987,508 patent/US20110200593A1/en not_active Abandoned
- 2011-10-28 JP JP2011236920A patent/JP2012072152A/ja active Pending
-
2012
- 2012-08-02 CY CY20121100687T patent/CY1113058T1/el unknown
-
2014
- 2014-02-21 US US14/186,149 patent/US20140242082A1/en not_active Abandoned
- 2014-06-13 US US14/303,973 patent/US20140294816A1/en not_active Abandoned
- 2014-07-18 JP JP2014147781A patent/JP2014237674A/ja not_active Withdrawn
-
2015
- 2015-01-16 US US14/598,365 patent/US20150202288A1/en not_active Abandoned
- 2015-01-30 US US14/610,332 patent/US20150202289A1/en not_active Abandoned
-
2016
- 2016-07-07 JP JP2016134790A patent/JP2017014215A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012072152A5 (cg-RX-API-DMAC7.html) | ||
| Hussain et al. | Vascular endothelial growth factor antagonists: promising players in the treatment of neovascular age-related macular degeneration | |
| JP7082599B2 (ja) | ヒト被験体における眼部障害の処置のための方法およびデバイス | |
| Yuan et al. | Ocular drug delivery nanowafer with enhanced therapeutic efficacy | |
| Molokhia et al. | Anterior eye segment drug delivery systems: current treatments and future challenges | |
| Wilson et al. | In vivo laser-mediated retinal ganglion cell optoporation using KV1. 1 conjugated gold nanoparticles | |
| JP2015528454A5 (cg-RX-API-DMAC7.html) | ||
| JP6836512B2 (ja) | 組織透過性ペプチドと抗血管内皮細胞成長因子製剤が融合された融合タンパク質を有効成分として含む眼疾患の予防及び治療用薬学的組成物 | |
| JP2017061467A5 (cg-RX-API-DMAC7.html) | ||
| JP2017524677A (ja) | 後眼部障害を処置するための方法およびデバイス | |
| CN109937053B (zh) | 用于治疗黄斑变性的含有mTOR抑制剂的药物组合物 | |
| JP2016522249A (ja) | 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用 | |
| JP2016523956A (ja) | 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用 | |
| US20220249517A1 (en) | Compositions and methods for treating noninfectious uveitis | |
| Jian et al. | Current choroidal neovascularization treatment | |
| Lee et al. | Intravitreal injection of AAV expressing soluble VEGF receptor-1 variant induces anti-VEGF activity and suppresses choroidal neovascularization | |
| JP2020523307A5 (cg-RX-API-DMAC7.html) | ||
| Kim | Novel approaches for retinal drug and gene delivery | |
| Shoeibi et al. | Effect of antiglaucoma agents on short-term intraocular pressure fluctuations after intravitreal bevacizumab injections | |
| Lee et al. | Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) antibody via Tower Microneedle | |
| JP6944463B2 (ja) | 眼疾患の治療のための組成物及び方法 | |
| Zhang et al. | Human umbilical cord-derived mesenchymal stem/stromal cells via suprachoroidal injection: A novel approach for experimental uveitis treatment | |
| Goldstein | Achieving drug delivery via the suprachoroidal space | |
| AU2020230409A1 (en) | Method for the treatment of a disease using pigment epithelium-derived factor (PEDF) | |
| Wasik et al. | Bevacizumab in conjunction with panretinal photocoagulation for neovascular glaucoma |